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ABSTRACT 
 
Oxaliplatin is a first-line chemotherapeutic agent used for the treatment of colorectal cancer. 
Its use is associated with severe gastrointestinal (GI) side-effects, associated with oxidative 
damage and neurotoxicity to the enteric neurons. Resveratrol is a potent anti-oxidant that has 
shown to exert protection against oxidative damage and neurotoxicity in other neurons and 
could therefore prevent oxaliplatin-induced damage to enteric neurons. We determined 
whether co-administration of resveratrol with oxaliplatin alleviates enteric neuron toxicity 
and GI dysfunction in mice. Colons were collected for immunohistochemical analysis of 
myenteric neurons and assessment of motor activity in organ-bath experiments. 
Morphological damage to the colonic mucosa and muscles was analysed. Oxaliplatin 
treatment induced translocation of nitrated proteins into the nuclei of myenteric neurons and 
significant damage to the mucosal lining, vacuolisation and a decrease in muscle thickness. 
This damage is linked to motor dysfunction due to inhibition of the amplitude of colonic 
contractions leading to chronic constipation. Co-treatment with resveratrol prevented 
oxaliplatin-induced neurotoxicity, alleviated damage to GI mucosa, crypts and muscle layer 
resulting in improved contractility and a decrease in constipation resveratrol could be 
integrated as part of a therapeutic regimen to help alleviate oxaliplatin-induced GI 
dysfunction. 
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1. Introduction 
 Colorectal cancer (CRC) has the highest incidence rate and the second highest 
mortality rate of all cancers worldwide [1, 2]. The first line of chemotherapeutic treatment for 
advanced CRC consists of the platinum-based compound oxaliplatin in combination with 5-
Fluorouracil and Leucovorin [3].  Although very effective in the treatment of CRC, there are 
many adverse effects associated with oxaliplatin treatment. The most severe and dose 
limiting properties of oxaliplatin treatment are the gastrointestinal (GI) side-effects such as 
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nausea, vomiting, diarrhoea and peripheral sensory neuropathy [4, 5]. These side-effects can 
persist for years even after treatment has ceased [6]. Dose limitations and in some instances, 
cessation of treatment, are often as a result of these side-effects. It is imperative that new 
treatment approaches are developed to prevent side-effects and increase the cytotoxic 
efficacy of treatment. The mechanisms by which these side-effects occur have been of 
interest lately. Recent findings suggest that oxidative damage and toxicity to the enteric 
neurons innervating the GI tract and controlling its functions may contribute to long-term 
side-effects of oxaliplatin treatment [7-9].  Thus, developing treatments that prevent oxidative 
damage to the enteric neurons is a viable pathway for improving patient quality of life. 
 Nitric oxide (NO) is produced by the activation of nitric oxide synthase (NOS), and is 
a widely distributed neurotransmitter located within both the central and peripheral nervous 
systems. NO has various location-dependant functions, and, in the GI tract acts as a mediator 
of vasodilation and GI relaxation [10, 11]. In the enteric neurons embedded in the GI tract 
wall, neuronal NOS (nNOS) is expressed by descending interneurons and inhibitory motor 
neurons supplying the intestinal smooth muscle [12]. Release of NO from neurons and 
smooth muscle is essential for the complex muscle co-ordinations that produce GI peristaltic 
motility [13, 14]. NO can become toxic in a reaction with superoxide to form peroxynitrite. 
Peroxynitrites are reactive nitrogen species (RNS) that have the ability to modify tyrosine 
residues in proteins to create nitrotyrosines.  Nitration of structural proteins has been shown 
to mediate oxidative damage to neurons and cause pathological complications [15]. The 
presence of RNS 3-nitrotyrosine (3-NT) in the nucleus of neuronal cells is an indicator of 
oxidative damage and neurotoxicity, and is associated with neuronal death [16].  
 Resveratrol (3,5,4′-trihydroxy-stilbene) is a potent polyphenol that is found naturally 
in grapes, plums, and peanuts [17]. There have been many studies reporting anti-oxidant, 
anti-inflammatory [18, 19]  neuroprotective [20-22]  and anti-cancer [23-26] effects of 
resveratrol. Studies investigating the anti-oxidant capabilities of resveratrol have 
demonstrated that it is a powerful scavenger of free radicals, can modulate and enhance 
cellular anti-oxidant defence mechanisms and has the ability to stimulate the synthesis of 
anti-oxidant enzymes [27, 28]. Additionally, resveratrol has been found to function 
synergistically with chemotherapeutic compounds to increase cytotoxic efficacy of anti-
cancer treatments in vivo and in vitro [29-33]. To date, no studies have investigated the 
ability of resveratrol to alleviate oxaliplatin-induced oxidative damage of the enteric neurons 
associated with GI side-effects. 
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2. Methods 
 
2.1. Animals and Ethical Approval 
 
 Male BALB/c mice aged 5-8 weeks (18 – 25g) were used in this study. Mice were 
supplied from the Animal Resources Centre (Perth, Australia). Animals were housed in 
groups of 3-5 and were kept in an animal holding room with a 12-hour light and dark cycle at 
approximately 22 °C with free access to food and water. The mice were allowed to 
acclimatise for at least one week before receiving injections. All experimental work in this 
study was approved by the Victoria University Animal Experimentation Ethics Committee 
and performed in accordance with the guidelines of the Australian National Health and 
Medical Research Council. 
 
2.2. Oxaliplatin Treatment 
 
 Mice received intraperitoneal (i.p.) injections of oxaliplatin (Tocris Bioscience, UK) 3 
mg/kg/dose 3 times a week with a 26 gauge needle for 2 weeks as previously reported [8]. 
Oxaliplatin was dissolved in sterile water in order to make 10-2 M stock solutions and 
refrigerated at -20°C. The stock was then defrosted and diluted further to make 10-3 mM 
solutions for intraperitoneal injections. The dose of oxaliplatin was calculated to be 
equivalent to standard human dose per body surface area [34, 35]. Vehicle-treated mice 
received sterile water via i.p. injections 3 times a week with a 26 gauge needle. Maximum 
volume did not exceed 200 µL per injection. Mice were euthanized via cervical dislocation 
14 days after the first oxaliplatin injection and colon tissues were collected for in vitro 
experiments.  
 
2.3. Resveratrol Treatment 
 
 Mice received i.p. injections of resveratrol (Sigma-Aldrich, Australia) at a 
500µg/kg/dose daily with a 26 gauge needle for 3 weeks. Resveratrol was dissolved in 100 % 
ethanol (EtOH) as per directions from the supplier. Daily resveratrol injections were made 
fresh each day as a 25 % dilution in sterile water. The resveratrol + oxaliplatin-treated group 
received the same dose of resveratrol injected daily 7 days prior to and every day during 
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oxaliplatin treatment. Maximum volume did not exceed 200 µL per injection. Vehicle-treated 
group received 25% EtOH+sterile water injected daily with a 26 gauge needle. The 
cumulative volume for mice receiving 2 injections in one day (resveratrol + oxaliplatin or 25 
% EtOH + sterile water) did not exceed 400µl. Oxaliplatin was administered 15 minutes 
(min) after resveratrol. Mice were euthanized via cervical dislocation 21 days after the first 
injection. Colon tissues were collected for in vitro experiments. 
 
2.4. Colonic Motility Assessment 
 
 The entire colon was removed from treated mice and set up in organ-bath chambers to 
record motor patterns ex vivo as described previously [9].Briefly, the colon was placed into 
warmed (35 °C), oxygenated physiological saline (composition in mM: NaCl 118, KCl 4.6, 
CaCl2 3.5, MgSO4 1.2, NaH2PO4 1, NaHCO3 25, d-Glucose 11; bubbled with 95%O2 and 5% 
CO2) until the faecal pallets were expelled. The empty colon was cannulated at both ends and 
arranged horizontally in organ-bath chambers.  The proximal end of the colon was connected 
to a reservoir containing oxygenated physiological saline to maintain a baseline intraluminal 
pressure. The distal end was attached to an outflow tube that provided a maximum of 2 cm 
H2O back-pressure. Organ baths were continuously perfused with oxygenated physiological 
saline solution and preparations were left to equilibrate for 30 min. Contractile activity of 
each segment was recorded with a Logitech Quickcam Pro camera positioned 7–8 cm above 
the preparation. Videos (4x15min) of each test condition were captured and saved in avi 
format using VirtualDub software (version 1.9.11).  
 Recordings were used to construct spatiotemporal maps using in-house edge detection 
software [36]. Spatiotemporal maps plot the diameter of the colon at all points during the 
recording allowing contractile motor patterns to be analysed with MatLab software (version 
12).  
 
2.5. Immunohistochemistry  
 
 Segments of the colon were placed in oxygenated phosphate-buffered saline (PBS) 
(pH 7.2) containing nicardipine (3 µM) (Sigma-Aldrich, Australia) for 20 min to inhibit 
smooth muscle contraction.  Samples were cut open along the mesenteric border, cleared of 
their contents, maximally stretched and dissected to expose the myenteric plexus.  Mucosa, 
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submucosa and circular muscle layers were removed and tissues containing longitudinal 
muscle and myenteric plexus were then fixed with Zamboni’s fixative (2 % formaldehyde, 
0.2 % picric acid) overnight at 4 °C. Preparations were cleared of fixative by washing 3 times 
for 10 min with Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich, Australia) followed by 3 x 10 
min washes with PBS. Fixed tissues were stored at 4°C in PBS for a maximum of 5 days. 
Wholemount preparations were incubated with 10% normal donkey serum (Chemicon, USA) 
for 1 hour at room temperature. Tissues were then washed (2 x 5 mins) with PBS and 
incubated with a primary antibody against 3-Nitrotyrosine (3-NT) (rabbit, 1:1000, Millipore,  
CA,  USA) overnight at 4 °C. Tissues were then washed 3 x 10 min in PBS before incubation 
with species-specific secondary antibody donkey anti-rabbit 488 (1:200, Jackson 
ImmunoResearch Laboratories, PA, USA) for 2 hours at room temperature. Wholemount 
preparations were given 3 final 10 min washes in PBS and then mounted to glass slides using 
fluorescent mounting medium (DAKO, Australia). 
 
2.6. Neuronal Cell Counting and Imaging 
 
 Wholemount preparations were observed as three dimensional (z-series) images under 
a Nikon Eclipse Ti laser scanning confocal microscope (Nikon, Japan), 8 randomly chosen 
images from each preparation were captured with a 20x objective and processed using NIS 
Elements software (Nikon, Japan). The number of neurons displaying translocation of 
nitrated proteins to the nuclei was quantified in myenteric ganglia within a 2mm2 area of each 
distal colon preparation. Fluorophores were visualized using excitation filters for Alexa 488 
(excitation wavelength 473nm). Z-series images were taken at step size of 1.75µm (1600 x 
1200 pixels). 
 
2.7. Histology  
 
 The distal colon was harvested and placed in a 10 % formalin solution overnight and 
transferred into 70 % ethanol the following day. Paraffin-embedded colon sections were cut 
into 5 µm thick sections and de-waxed in a 60 ˚C oven for 30 min. To examine the 
morphological changes to the colon, a standard Hematoxylin and Eosin staining protocol was 
followed [37]. Ten sections per preparation were analysed. All images were analyzed blindly. 
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2.8. Data and Statistical Analysis  
 
 Sample size was calculated based on our previous studies on enteric neuropathy and 
intestinal dysmotility associated with chemotherapy [8, 38].To detect a 30% change at a 
power 0.8 and α = 0.05 with 10% SD, the effect size should be minimum n=5 animals per 
group as calculated by the GPOWER program. Data were assessed using one way ANOVA 
and Tukey’s post-hoc test. Analyses were performed using Graph Pad Prism (Graph Pad 
Software Inc., CA, USA). Data are presented as mean ± standard error of the mean (SEM). 
Value differences were considered statistically significant at P<0.05.  
 
3. Results 
 
3.1. Treatment with resveratrol prevented oxaliplatin-induced translocation of nitrated 
proteins into the nucleus of myenteric neurons  
 
 Repeated oxaliplatin administration in mice was associated with a significant 
(***P<0.001) increase in the translocation of nitrated proteins into the nuclei of myenteric 
neurons (38±1 neurons/2mm2) when compared to vehicle-treated mice (17±1 neurons/2mm2) 
(Figure 1A-B). Resveratrol administered in combination with oxaliplatin prevented 
oxaliplatin-induced translocation of nitrated proteins into neuronal nuclei (17±1 
neurons/2mm2). Resveratrol treatment alone had no effect on the amount of translocation 
(12±1 neurons/2mm2) similar to the vehicle group. 
 
3.2. Treatment with resveratrol prevented oxaliplatin-induced mucosal damage and loss 
of smooth muscle in the distal colon 
 
 Gross morphological assessment of distal colon segments from treated and untreated 
mice showed significant changes had occurred. Oxaliplatin-treated mice demonstrated 
significant damage to the mucosal lining, vacuolisation, and a decrease in muscle thickness 
(73±17µm; ***P<0.001) when compared to vehicle (240±5 µm) and resveratrol-treated mice 
(243±12 µm) (Figure 1C-D). Resveratrol + oxaliplatin treatment alleviated damage to the 
mucosa and muscle layer width (153±20 µm) but was not comparable to vehicle-treated 
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mice, with a decrease in muscle width (*P<0.05), but was significantly different to 
oxaliplatin-treated group.  
 
3.3. Treatment with resveratrol alleviated oxaliplatin-induced changes to colonic motor 
activity 
 
 Oxaliplatin-treated mice demonstrated reduction in the amplitude of colonic 
contractility, with the change in diameter (48±13mm) significantly less (***P<0.001) than 
that observed in vehicle-treated mice (129±9mm) (Figure 2A-B). Administration of 
resveratrol in conjunction with oxaliplatin alleviated the reduction in the amplitude of 
contractions and the change in diameter between relaxation and contraction was not 
significantly different to vehicle-treated group (117±8mm). Resveratrol treatment alone had 
no effect on the change in diameter of the distal colon (142±4mm). 
 
3.4. Treatment with resveratrol alleviated oxaliplatin-induced constipation 
 
 The number of pellets present in the colon of mice after culling is an indication of 
colonic function. Chronic oxaliplatin-treatment caused significant constipation (6±0.3 
pellets/colon, ***P<0.001) when compared to vehicle (1.7±0.2 pellets/colon) and resveratrol 
(1.8±0.3 pellets/colon) treatments (Figure 2C). Resveratrol in combination with oxaliplatin 
was able to partially alleviate this (3.3±0.3 pellets/colon), however the level of constipation 
was still increased (*P<0.05) when compared to vehicle-treated mice. 
 
4. Discussion  
 
 Here we present one of the first studies to demonstrate that resveratrol administered in 
conjunction with oxaliplatin prevents oxidative damage and neurotoxicity as well as 
alleviating colonic dysfunction and constipation. 
 
4.1. Resveratrol alleviates oxaliplatin-induced oxidative damage in enteric neurons 
 
 We used the marker anti-3-NT antibody to identify the translocation of nitrated 
proteins in neuronal nuclei as an indicator of oxidative damage and neurotoxicity. 
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Translocation occurred most significantly in the enteric neurons of oxaliplatin-treated mice, 
and was reduced to the level of vehicle-treated group in the resveratrol + oxaliplatin-treated 
animals.  Previous studies have shown translocation of nitrotyrosine in myenteric neurons 
following ischemia and reperfusion in mice [39] and induction of colitis in rats [40]. 
Accumulation and translocation of nitrotyrosine has been linked to protein misfolding, 
mitochondrial dysfunction, neuronal degeneration [41] and an increased susceptibility to NO-
induced apoptosis [42]. The results of this study are in agreement with previously reported 
increased level of superoxide production, cytochrome c release and apoptosis in myenteric 
neurons after oxaliplatin treatment [9]. Co-treatment with resveratrol significantly alleviated 
the translocation of nitrotyrosine when compared to the oxaliplatin-only treated group. 
Resveratrol has previously demonstrated inhibitory effects on peroxynitrite-mediated 
oxidation of proteins and lipids [43] and in prevention of nitrative and oxidative damage 
through upregulation of anti-oxidant enzyme superoxide dismutase isoforms [44] and 
activation of the Sirt1/AMPK and the Nrf2/anti-oxidant defence pathways [45]. 
 
4.2. Resveratrol ameliorates oxaliplatin-induced changes to distal colon morphology 
 
 Oxaliplatin administration was associated with a significant reduction in colonic 
smooth muscle thickness, which is similar to our previously published data [9].  As well as 
the effects on smooth muscle, oxaliplatin caused severe damage to colon morphology, one of 
these being abnormal vacuolisation within the intestinal crypts which has previously been 
reported to be an indicator of inflammation [46]. Co-administration of resveratrol with 
oxaliplatin had a protective effect on the colon, with the resveratrol + oxaliplatin-treated mice 
demonstrating healthy mucosal lining, crypt structure and muscle thickness. Resveratrol was 
previously reported to prevent GI inflammation [47, 48], but this is the first study to 
demonstrate protection from oxaliplatin-induced inflammation.  
 
4.3. Resveratrol alleviates oxaliplatin-induced colonic dysfunction and constipation 
 
 Significant reduction in the amplitude of colonic contractions was observed in the 
colons from oxaliplatin-treated mice. This was associated with an increase in the number of 
pellets present in the colons of oxaliplatin-treated mice, indicating constipation due to 
insufficient propulsion of faecal pellets through the distal colon. These results, combined with 
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the increase in translocation of nitrated proteins to neuronal nuclei and previously reported 
loss of myenteric neurons [8, 9] as well as morphological changes in the colonic smooth 
muscles observed in the colons from oxaliplatin-treated mice, suggest that the decrease in the 
amplitude of colonic contractions is due to a decrease in neuronal input from motor neurons 
and less muscle mass available to perform contraction. Our observations are in agreement 
with previous studies reporting oxaliplatin-induced neuronal loss and alternations in nNOS 
expression leading to colonic dysmotility [8] and cisplatin-induced inhibition of intestinal 
transit [7]. Co-treatment with resveratrol alleviated oxaliplatin-induced changes in colonic 
contractile activity and symptoms of chronic constipation. 
 
5. Conclusion  
 
 The results of this study demonstrate that oxaliplatin treatment causes neurotoxicity 
through nitrate translocations in the nuclei of enteric neurons and damages colon 
morphology. This damage is linked to motor dysfunction due to inhibition of the amplitude of 
colonic contractions leading to constipation. Co-treatment with resveratrol prevented 
neuronal toxicity and alleviated damage to GI mucosa, crypts and muscle layer resulting in 
improved contractility and a decrease in constipation. Resveratrol poses great therapeutic 
potential to prevent and alleviate oxaliplatin-induced oxidative damage to improve patient 
quality of life. Future research is required to determine the effects of resveratrol on the 
efficacy of oxaliplatin in an in vivo model of colorectal cancer and on the specific 
mechanisms used to infer its anti-oxidant/neuroprotective and anti-inflammatory actions. 
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Figure Legends 
 
Figure 1. Effect of oxaliplatin treatment on enteric neurons and colon morphology. 
Antibody against 3-Nitrotyrosine (3-NT) was used to label nitrated proteins within the 
myenteric plexus (A’-A’’’’). The number of neurons per 2 mm2 displaying translocation of 
nitrated proteins to the nuclei was higher in the oxaliplatin-treated group compared to 
vehicle-treated. Resveratrol + oxaliplatin-treated mice showed significantly less translocation 
of 3-NT when compared to oxaliplatin. (B) Statistical analysis of the number of neurons 
displaying translocation of nitrated proteins into the nucleus. Data presented as mean ± 
standard error of the mean (S.E.M). ***P<0.001 compared to all other groups (n=5 
mice/group).  (C’-C’’’’) Gross morphological changes in the colon following repeated in vivo 
oxaliplatin administration.  Mucosal damage (a), abnormal vacuolisation (b), crypt length (c), 
and muscle thickness were affected in oxaliplatin-treated mice (C’’), these changes were 
prevented by co-treatment with resveratrol (C’’’’). (D) Statistical analysis of the muscle layer 
thickness in the colon preparations from treated mice. Data presented as mean ± S.E.M. 
*P<0.05 compared to oxaliplatin-treated group, ***P<0.001 compared to vehicle and 
resveratrol-only treated groups (n=5 mice/group, 10 sections per preparation from each 
animal).  
 
Figure 2. Effect of oxaliplatin on contractility of the distal colon. (A) A vertical slice map 
displaying the change in diameter of distal colon segments during peristaltic motility is 
presented. vehicle-treated (black), and resveratrol + oxaliplatin-treated (green) mice display 
similar diameters during relaxation and contraction and represent normal motor patterns. 
Colons from oxaliplatin-treated mice (red) display a reduction in the amplitude of colonic 
contractions. (B) Statistical analysis of changes in diameter of the distal colon from treated 
mice. Data presented as mean ± standard error of the mean (S.E.M). ***P<0.001 compared 
to all other groups (n=5 mice/group). (C) Statistical analysis of the number of pellets present 
in the mouse colon. High numbers of pellets indicate constipation. *P<0.05 compared to 
vehicle-treated group, ***P<0.001 compared to all other groups (n=5 mice/group). 
13 
 
References 
 
[1] Astin M, Griffin T, Neal R. The diagnostic value of symptoms for colorectal cancer in primary care: 
a systematic review. British Journal of General Practice. 2011;61:e231–e43. 
[2] Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality 
rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893-907. 
[3] Bhushan S, McLeod H, Walko CM. Role of Pharmacogenetics as Predictive Biomarkers of 
Response and/or Toxicity in the Treatment of Colorectal Cancer. Clinical Colorectal Cancer. 
2009;8:15-21. 
[4] Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. The Annals of pharmacotherapy. 
2005;39:128-35. 
[5] Grothey A. Clinical Management of Oxaliplatin-Associated Neurotoxicity. Clinical Colorectal 
Cancer. 2005;5, Supplement 1:S38-S46. 
[6] Denlinger CS, Barsevick AM. The challenges of colorectal cancer survivorship. Journal of the 
National Comprehensive Cancer Network : JNCCN. 2009;7:883-93; quiz 94. 
[7] Vera G, Castillo M, Cabezos P, Chairlone A, Martín M, Gori A. Enteric neuropathy evoked by 
repeated cisplatin in the rat. Neurogastroenterology & Motility. 2011;23:370-78. 
[8] Wafai L, Taher M, Jovanovska V, Bornstein JC, Dass CR, Nurgali K. Effects of oxaliplatin on mouse 
myenteric neurons and colonic motility. Frontiers in neuroscience. 2013;7:30. 
[9] McQuade RM, Carbone SE, Stojanovska V, Rahman A, Gwynne RM, Robinson AM, et al. Role of 
oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. British 
journal of pharmacology. 2016;173:3502-21. 
[10] Bornstein JC, Costa M, Grider JR. Enteric motor and interneuronal circuits controlling motility. 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility 
Society. 2004;16 Suppl 1:34-8. 
[11] Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the 
gastrointestinal tract. Journal of gastroenterology. 2003;38:421-30. 
[12] Lecci A, Santicioli P, Maggi CA. Pharmacology of transmission to gastrointestinal muscle. Current 
opinion in pharmacology. 2002;2:630-41. 
[13] Roberts RR, Bornstein JC, Bergner AJ, Young HM. Disturbances of colonic motility in mouse 
models of Hirschsprung's disease. American journal of physiology Gastrointestinal and liver 
physiology. 2008;294:G996-G1008. 
[14] Roberts RR, Murphy JF, Young HM, Bornstein JC. Development of colonic motility in the 
neonatal mouse-studies using spatiotemporal maps. American journal of physiology Gastrointestinal 
and liver physiology. 2007;292:G930-8. 
[15] Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and 
ugly. The American journal of physiology. 1996;271:C1424-37. 
[16] Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW. Mass spectrometric quantification of 
3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-
tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. The Journal of 
biological chemistry. 1999;274:34621-8. 
[17] Ergun O, Ergun G, Oktem G, Selvi N, Dogan H, Tuncyurek M, et al. Enteral resveratrol 
supplementation attenuates intestinal epithelial inducible nitric oxide synthase activity and mucosal 
damage in experimental necrotizing enterocolitis. Journal of pediatric surgery. 2007;42:1687-94. 
[18] Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol 
in microglial activation. European journal of pharmacology. 2010;636:1-7. 
[19] Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, Cittadini A. Resveratrol, a natural 
phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutation 
research. 2001;496:171-80. 
14 
 
[20] Virgili M, Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic 
administration of the red wine antioxidant agent, trans-resveratrol in rats. Neuroscience letters. 
2000;281:123-6. 
[21] Sinha K, Chaudhary G, Gupta YK. Protective effect of resveratrol against oxidative stress in 
middle cerebral artery occlusion model of stroke in rats. Life sciences. 2002;71:655-65. 
[22] Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, et al. Resveratrol protects against 
global cerebral ischemic injury in gerbils. Brain research. 2002;958:439-47. 
[23] Feng Y, Yang Y, Fan C, Di S, Hu W, Jiang S, et al. Pterostilbene Inhibits the Growth of Human 
Esophageal Cancer Cells by Regulating Endoplasmic Reticulum Stress. Cellular physiology and 
biochemistry : international journal of experimental cellular physiology, biochemistry, and 
pharmacology. 2016;38:1226-44. 
[24] Tang Q, Li G, Wei X, Zhang J, Chiu JF, Hasenmayer D, et al. Resveratrol-induced apoptosis is 
enhanced by inhibition of autophagy in esophageal squamous cell carcinoma. Cancer letters. 
2013;336:325-37. 
[25] Liu P, Liang H, Xia Q, Li P, Kong H, Lei P, et al. Resveratrol induces apoptosis of pancreatic 
cancers cells by inhibiting miR-21 regulation of BCL-2 expression. Clinical & translational oncology : 
official publication of the Federation of Spanish Oncology Societies and of the National Cancer 
Institute of Mexico. 2013;15:741-6. 
[26] Yang Q, Wang B, Zang W, Wang X, Liu Z, Li W, et al. Resveratrol inhibits the growth of gastric 
cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PLoS One. 
2013;8:e70627. 
[27] Fremont L. Biological effects of resveratrol. Life sciences. 2000;66:663-73. 
[28] Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nature reviews 
Drug discovery. 2006;5:493-506. 
[29] Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, et al. 
Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in 
orthotopic mouse model of human pancreatic cancer. International journal of cancer. 2010;127:257-
68. 
[30] Ma L, Li W, Wang R, Nan Y, Wang Q, Liu W, et al. Resveratrol enhanced anticancer effects of 
cisplatin on non-small cell lung cancer cell lines by inducing mitochondrial dysfunction and cell 
apoptosis. International journal of oncology. 2015;47:1460-8. 
[31] Cheng YJ, Chang MY, Chang WW, Wang WK, Liu CF, Lin ST, et al. Resveratrol Enhances 
Chemosensitivity in Mouse Melanoma Model Through Connexin 43 Upregulation. Environmental 
toxicology. 2015;30:877-86. 
[32] Hu S, Li X, Xu R, Ye L, Kong H, Zeng X, et al. The synergistic effect of resveratrol in combination 
with cisplatin on apoptosis via modulating autophagy in A549 cells. Acta biochimica et biophysica 
Sinica. 2016;48:528-35. 
[33] Kaminski BM, Weigert A, Scherzberg MC, Ley S, Gilbert B, Brecht K, et al. Resveratrol-induced 
potentiation of the antitumor effects of oxaliplatin is accompanied by an altered cytokine profile of 
human monocyte-derived macrophages. Apoptosis : an international journal on programmed cell 
death. 2014;19:1136-47. 
[34] Renn CL, Carozzi VA, Rhee P, Gallop D, Dorsey SG, Cavaletti G. Multimodal assessment of painful 
peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain. 
2011;7:29. 
[35] Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, et al. Heated intra-
operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal 
carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Annals of oncology. 
2004;15:1558-65. 
15 
 
[36] Gwynne RM, Thomas E, Goh S, Sjövall H, Bornstein J. Segmentation induced by intraluminal 
fatty acid in isolated guinea-pig duodenum and jejunum. The Journal of physiology. 2004;556:557-
69. 
[37] Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell 
sections. CSH protocols. 2008;2008:pdb prot4986. 
[38] McQuade R, Stojanovska V, Donald E, Abalo R, Bornstein JC, Nurgali K. Gastrointestinal 
dysfunction and enteric neurotoxicity following treatment with anti-cancer chemotherapeutic agent 
5-Fluorouracil. Neurogastroenterology & Motility. 2016. 
[39] Rivera LR, Thacker M, Pontell L, Cho HJ, Furness JB. Deleterious effects of intestinal 
ischemia/reperfusion injury in the mouse enteric nervous system are associated with protein 
nitrosylation. Cell and tissue research. 2011;344:111-23. 
[40] Zingarelli B, O'Connor M, Hake PW. Inhibitors of poly (ADP-ribose) polymerase modulate signal 
transduction pathways in colitis. European journal of pharmacology. 2003;469:183-94. 
[41] Nakamura T, Lipton SA. Emerging roles of S-nitrosylation in protein misfolding and 
neurodegenerative diseases. Antioxidants & redox signaling. 2008;10:87-101. 
[42] Savidge TC. S-nitrosothiol signals in the enteric nervous system: lessons learnt from big brother. 
Frontiers in neuroscience. 2011;5:31. 
[43] Olas B, Nowak P, Kolodziejczyk J, Ponczek M, Wachowicz B. Protective effects of resveratrol 
against oxidative/nitrative modifications of plasma proteins and lipids exposed to peroxynitrite. J 
Nutr Biochem. 2006;17:96-102. 
[44] Xia N, Daiber A, Habermeier A, Closs EI, Thum T, Spanier G, et al. Resveratrol reverses 
endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. The Journal of 
pharmacology and experimental therapeutics. 2010;335:149-54. 
[45] Tamaki N, Cristina Orihuela-Campos R, Inagaki Y, Fukui M, Nagata T, Ito HO. Resveratrol 
improves oxidative stress and prevents the progression of periodontitis via the activation of the 
Sirt1/AMPK and the Nrf2/antioxidant defense pathways in a rat periodontitis model. Free radical 
biology & medicine. 2014;75:222-9. 
[46] Valentin-Vega YA, Okano H, Lozano G. The intestinal epithelium compensates for p53-mediated 
cell death and guarantees organismal survival. Cell death and differentiation. 2008;15:1772-81. 
[47] Rahal K, Schmiedlin-Ren P, Adler J, Dhanani M, Sultani V, Rittershaus AC, et al. Resveratrol has 
antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's 
disease. Inflamm Bowel Dis. 2012;18:613-23. 
[48] Sanchez-Fidalgo S, Cardeno A, Villegas I, Talero E, de la Lastra CA. Dietary supplementation of 
resveratrol attenuates chronic colonic inflammation in mice. European journal of pharmacology. 
2010;633:78-84. 
 
 
